GET DAILY SIGNALSNanobiotix (NBTX) Advances +12% in 30 Days Following Key Clinical Data
Key Takeaways
- Nanobiotix (NBTX) shares advanced roughly 12% over the trailing 30 days, climbing from about $25.75 to near $28.92.
- The gain reflects a sharp rebound off a mid-October trough near $21, though the stock remains down approximately 26% over the last quarter.
- Final Phase 1 data for JNJ-1900 (NBTXR3) in anti-PD-1-resistant melanoma, presented at ESMO 2026, showed a 41.7% overall response rate and supported the recovery.
- The appointment of Arnd Christ as chief financial officer and continued progress on the Johnson & Johnson-partnered pipeline reinforced the narrative.
- As a clinical-stage, pre-revenue biotechnology company, Nanobiotix remains dependent on milestone payments, financing, and pipeline execution.
- For more detail on valuation and expectations, explore the company’s Price Targets, Earnings, and Forecast pages.
- To monitor AI-driven trading activity across the market, explore Trending AI Robots.
Nanobiotix Background and Pipeline Focus
Nanobiotix is a Paris, France-based late-stage clinical biotechnology company developing physics-based nanotherapeutics. Its lead candidate, NBTXR3, now known as JNJ-1900, consists of hafnium oxide nanoparticles meant to boost radiotherapy effects within tumors while sparing nearby healthy tissue. This program is licensed to JNJ, which is advancing trials such as the pivotal NANORAY-312 study in head and neck cancer and the CONVERGE Phase 2 study in non-small cell lung cancer.
The company maintains over 30 patent families across three nanotechnology platforms targeting oncology and other areas. Listed on both Euronext Paris and Nasdaq under NBTX, the stock draws attention around clinical readouts, regulatory steps, and partnership economics with JNJ. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recent Price Action: 30-Day Gain Versus Quarterly Decline
Over the past 30 days, NBTX rose about 12%, moving from a close near $25.75 to roughly $28.92. The path was uneven, with a dip to around $21 in mid-October followed by a quick climb toward $34 late in the month before easing back in early November.
The three-month view shows a different picture. The stock is down approximately 26% from levels near $39 in early August, after sliding through mid-October. The recent recovery therefore marks a partial retracement of that broader drop rather than a full return to earlier peaks.
Drivers Behind the 30-Day Move
Clinical data stood out as the main catalyst. On October 24, 2026, Nanobiotix released final results from the Phase 1 Study 1100 testing JNJ-1900 (NBTXR3) plus immune checkpoint inhibitors in anti-PD-1-resistant advanced cutaneous melanoma. Among 24 heavily pre-treated patients, the overall response rate reached 41.7%, with median progression-free survival of 6.9 months and median overall survival of 17.8 months, all with a manageable safety profile. These findings were shared at the ESMO 2026 meeting.
The late-October price lift aligned with this update and broader pipeline optimism. On October 1, the company named Arnd Christ as chief financial officer, adding more than 20 years of public biotech experience. Some pullback from the late-month highs into early November followed questions around Phase 3 timing and lender priorities.
Factors Shaping Performance Over the Quarter
The past three months featured notable volatility more than any single headline. Through September and early October, the shares drifted lower amid no immediate Phase 3 readout, dilution concerns after the May 2026 offering, and softer sentiment across clinical-stage biotech names.
Late-October updates helped offset some of that pressure, including full-cohort Phase 1 results in recurrent non-small cell lung cancer and the ESMO melanoma data. The Johnson & Johnson partnership stays central, with the NANORAY-312 study in cisplatin-ineligible head and neck cancer remaining the key upcoming inflection point.
Key Milestones on the Horizon
Looking forward, attention centers on the JNJ-sponsored pipeline. The NANORAY-312 Phase 3 trial in head and neck cancer is the primary catalyst; adjustments to conduct the final analysis sooner with fewer events could shift readout timing. Further data from the CONVERGE Phase 2 lung cancer study and Study 1100 updates will also influence views.
On the financial side, Nanobiotix reported €110.9 million in cash and equivalents as of June 30, 2026, and projects a runway into 2029. Investors will track milestone payments and revenue under the Johnson & Johnson deal, capital decisions, and any new financing. Broader market conditions and biotech sector sentiment remain relevant external factors.
Using Tickeron AI Tools for Market Context
In my view, staying on top of automated trading signals adds useful perspective when following names like NBTX. I recently reviewed Tickeron’s AI Daily Buy/Sell Signals to gauge current momentum patterns across similar biotech holdings. This approach helps frame how the recent price action fits into wider market activity without replacing fundamental analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for NBTX turns positive, indicating new upward trend
NBTX saw its Momentum Indicator move above the 0 level on October 21, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 101 similar instances where the indicator turned positive. In 84 of the 101 cases, the stock moved higher in the following days. The odds of a move higher are at 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for NBTX just turned positive on October 20, 2026. Looking at past instances where NBTX's MACD turned positive, the stock continued to rise in 35 of 45 cases over the following month. The odds of a continued upward trend are 78%.
Following a +17.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where NBTX advanced for three days, in 188 of 232 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
The 10-day RSI Indicator for NBTX moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 22 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 76%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
NBTX moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for NBTX moved below the 200-day moving average on October 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NBTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
NBTX broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for NBTX entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-47.850) is normal, around the industry mean (3.162). P/E Ratio (-28.780) is within average values for comparable stocks, (-1.064). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.622) among similar stocks. P/S Ratio (48.077) is also within normal values, averaging (439.647).
The Tickeron PE Growth Rating for this company is 28 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. NBTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 61 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement